Global markets stumbled on Monday, with Asian shares and U.S. futures declining sharply. The sell-off was led by a significant pullback in South Korean tech stocks amid renewed concerns over an AI sector bubble, while oil prices dropped over $2 per barrel.
A federal appeals court has thrown out a Justice Department misconduct complaint against a judge who blocked deportations to El Salvador's notorious prisons, citing a lack of evidence. The ruling highlights ongoing tensions between the judiciary and executive branch over immigration enforcement.
From Mussolini's Rome-Berlin Axis to Bush's 'Axis of Evil,' the term has evolved from a descriptive label to a powerful political tool, framing global rivalries and shaping diplomatic realities.
Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.
As the ASX braces for a turbulent week amid rate hike fears, investors are scouring the market for resilient opportunities. We delve into three penny stocks—spanning energy, retail, and healthcare—that combine financial stability with distinct growth narratives for the discerning investor.
A Zamboni operator has died following a workplace collision at the Edora Pool Ice Center, prompting a city-wide safety review and temporary closure of the rink.
The death of Alicia Harnishfeger, discovered under a downtown bridge during a severe cold snap, has sparked conversations about systemic failures in addressing homelessness intertwined with mental health and substance abuse crises.
While the frequency of U.S. government shutdowns has declined since the 1990s, a deepening partisan divide has transformed them into longer, more damaging stalemates, with 22 closures since 1976 imposing growing costs on federal operations and the public.
Health and Human Services Secretary Robert F. Kennedy Jr. has publicly addressed the deep divisions within America's most storied political family, following the death of his cousin Tatiana Schlossberg and amidst ongoing policy controversies that have placed him at odds with his relatives.
A discounted cash flow analysis suggests shares of the Malaysian poultry and seafood firm may be overvalued at current levels, raising questions for investors.
Micron Technology, a key player in memory chips, is poised for explosive earnings growth fueled by insatiable AI demand. Yet, its cyclical nature and commoditized market pose significant long-term risks for investors.
As artificial intelligence drives an unprecedented surge in electricity demand, one utility company—Constellation Energy—is uniquely positioned with its vast nuclear fleet to meet the need, turning an industry-wide bottleneck into a significant growth opportunity.
From split boxes to crushed pallets, transit damage remains a multi-billion dollar drain on global supply chains. We examine the systemic mismatches between packaging design and the harsh realities of modern logistics.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
Exclusive testimony from Dr. Mohamed Ibrahim, who fled the last hospital in Sudan's strategic el-Fasher, details a three-day ordeal of hiding from paramilitary forces, witnessing mass casualties, and surviving a kidnapping and ransom demand—shedding light on a siege the U.N. calls a 'massive crime scene.'
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.
